Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A Co-administered With Zilbrix™ Hib and Polio Sabin™

The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of African Sub-Saharan infants with pneumococcal conjugate vaccine GSK 1024850A co-administered with a diphtheria, tetanus, whole cell pertussis (DTPw)-combined vaccine and oral polio vaccine in children during the first 4 months of life.

本研究旨在评估撒哈拉以南非洲婴儿在出生后前4个月内完成肺炎球菌结合疫苗（pneumococcal conjugate vaccine）GSK 1024850A基础免疫接种，并与白喉、破伤风、全细胞百日咳（DTPw）联合疫苗及口服脊髓灰质炎疫苗（oral polio vaccine）联合接种后，以抗体应答为评价指标的免疫原性，以及以主动申报症状、非主动申报症状与严重不良事件为评价指标的安全性及反应原性。